Colon and Rectal Cancer – David Ilson, MD, and Robert Figlin, MD, discuss recent clinical advances in colon and rectal cancer from ASCO20 Virtual

Colon and Rectal Cancer – David Ilson, MD, and Robert Figlin, MD, discuss recent clinical advances in colon and rectal cancer from ASCO20 Virtual

Monday June 8, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and David Ilson, MD, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, discuss the progress in colon and rectal cancer presented at ASCO20

Non Small Cell Lung Cancer (NSCLC) – Edward Garon, MD, and Robert Figlin, MD, discuss promising agents in development for the management of NSCLC from ASCO20

Thursday June 11, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Edward Garon, MD, Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, Associate Professor of Medicine, David Geffen School of Medicine, UCLA, discuss promising agents in development for the management of NSCLC from ASCO20

Waldenstrom macroglobulinemia – Constantine Tam, MD, and Robert Figlin, MD, discuss recent clinical advances in the treatment of Waldenstrom macroglobulinemia from ASCO20

Monday June 8, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Constantine Tam, MD, Haematologist and Disease Group Lead, Low Grade Lymphoma and Chronic Lymphocytic Leukemia, Peter MacCallum Cancer Centre, discuss the progress in Waldenstrom macroglobulinemia from ASCO20

Featured Videos

Debu Tripathy, MD, discusses recent FDA approvals and HER2+ metastatic breast cancer management

Edward Garon, MD, discusses length of use when combining I-O with chemotherapy in 1st line NSCLC

Sara Hurvitz, MD, describes the recently reported results using PARP inhibition and cisplatin